<DOC>
	<DOCNO>NCT01144637</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled Phase III trial evaluate immunogenicity safety three consecutive production lot IMVAMUNE® ( MVA-BN® ) smallpox vaccine healthy , vaccinia-naïve subject .</brief_summary>
	<brief_title>A Trial Evaluate Immunogenicity Safety Three Consecutive Production Lots IMVAMUNE® ( MVA-BN® ) Smallpox Vaccine Healthy , Vaccinia-naïve Subjects</brief_title>
	<detailed_description />
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject , 18 40 year age The subject read , sign date informed consent form , advise risk benefit trial language understood subject prior performance trial specific procedure BMI ≥ 18.5 &lt; 35 Women childbearing potential ( WOCBP ) must use acceptable method contraception 30 day prior first vaccination , must agree use acceptable method contraception trial , must avoid become pregnant least 28 day last vaccination . A woman consider childbearing potential unless postmenopausal history hysterectomy ( Acceptable contraception method restrict abstinence , barrier contraceptive , intrauterine contraceptive device license hormonal product ) WOCBP must negative serum pregnancy test screen negative urine pregnancy test within 24 hour prior vaccination White blood cell ≥ 2,500/mm3 &lt; ULN Absolute neutrophil count ( ANC ) within normal limit Hemoglobin within normal limit Platelets within normal limit Adequate renal function define calculated Creatinine Clearance ( CrCl ) &gt; 60 ml/min estimate CockcroftGault equation : For men : ( 140 age year ) x ( body weight kg ) ÷ ( serum creatinine mg/dl x 72 ) = CrCl ( ml/min ) For woman : multiply result 0.85 = CrCl ( ml/min ) . Adequate hepatic function define : . Total bilirubin ≤ 1.5 x ULN absence evidence significant liver disease b. Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase ≤ 1.5 x ULN Troponin I &lt; 2 x ULN Electrocardiogram ( ECG ) without clinically significant finding ( e.g . kind atrioventricular intraventricular condition block complete left right bundle branch block , AV node block , QTc PR prolongation , premature atrial contraction atrial arrhythmia , sustain ventricular arrhythmia , two premature ventricular contraction row , ST elevation consistent ischemia ) Exclusion criterion Typical vaccinia scar Known suspect history smallpox vaccination History vaccination poxvirusbased vaccine US Military service prior 1991 January 2003 Pregnant breastfeed woman Uncontrolled serious infection , i.e . respond antimicrobial therapy History serious medical condition , opinion investigator would compromise safety subject would limit subject 's ability complete trial History active autoimmune disease , person vitiligo thyroid disease take thyroid replacement exclude Known suspect impairment immunologic function include , limited , HIV Infection , clinically significant liver disease ( include chronic active HBV HCV ) , diabetes mellitus , moderate severe kidney impairment History malignancy squamous cell basal cell skin cancer , unless surgical excision consider achieved cure . Subjects history skin cancer must vaccinate previous tumor site History clinical manifestation clinically significant severe hematological , pulmonary , central nervous , cardiovascular gastrointestinal disorder Clinically significant mental disorder adequately control medical treatment History coronary heart disease , myocardial infarction , angina pectoris , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , uncontrolled high blood pressure , heart condition care doctor Known history immediate family member ( father , mother , brother , sister ) onset ischemic heart disease age 50 year Ten percent great risk develop myocardial infarction coronary death within next 10 year use National Cholesterol Education Program 's risk assessment tool ( http : //hin.nhlbi.nih.gov/atpiii/calculator.asp ? usertype=prof ) NOTE : This criterion apply subject 20 year age older Active history chronic alcohol abuse and/or intravenous and/or nasal drug abuse ( within past 6 month ) Known allergy IMVAMUNE® vaccine constituent , e.g . tris ( hydroxymethyl ) amino methane , include know allergy egg aminoglycosides History anaphylaxis severe allergic reaction vaccine Acute disease ( illness without fever ) time enrollment Body temperature ≥100.4°F ( ≥38.0°C ) time enrollment Having receive vaccination plan vaccination live vaccine within 30 day prior trial vaccination Having receive vaccination plan vaccination kill vaccine within 14 day prior trial vaccination Chronic systemic administration ( defined 14 day ) &gt; 5 mg prednisone ( equivalent ) /day immunemodifying drug period start three month prior administration vaccine end last physical trial visit ( V5 ) Post organ transplant subject whether receive chronic immunosuppressive therapy Administration plan administration immunoglobulin and/or blood product period start three month prior administration vaccine end last physical trial visit ( V5 ) Use investigational nonregistered drug vaccine trial vaccine within 30 day precede first dose trial vaccine , plan administration drug trial period Trial personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>